Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients with Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial

Clinical Infectious Diseases

Volumn 65, Issue 4, 2017, Pages 535-543

  Tine, Roger C ^a   Sylla, Khadime ^a   Faye, Babacar T ^a   Poirot, Eugenie ^b   Fall, Fatou B ^c   Sow, Doudou ^a   Wang, Duolao ^d   Ndiaye, Magatte ^a   Ndiaye, Jean Louis ^a   Greenwood, Brian ^d   Gaye, Oumar ^a   Milligan, Paul ^d  

^a UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c de la Recherche et des Statistiques Division du Système d Information Sanitaire et Social   (Senegal)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

hemoglobin; plasmodium; primaquine; safety; Senegal

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; PRIMAQUINE; ANTIMALARIAL AGENT;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMETOCYTE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENEGAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; URINE COMPOSITION DISORDER; ADOLESCENT; BLOOD; MIDDLE AGED; PARASITEMIA; PARASITOLOGY; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; FEMALE; HEMOGLOBINS; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIMAQUINE; SENEGAL; YOUNG ADULT;

EID: 85026876469     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix355     Document Type: Article

References (37)

1. WHO. World malaria report 2016. Geneva: World Health Organization, 2016.
2. Cotter C, Sturrock HJ, Hsiang MS, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 2013; 382:900-11.
3. Tatem AJ, Smith DL, Gething PW, Kabaria CW, Snow RW, Hay SI. Ranking of elimination feasibility between malaria-endemic countries. Lancet 2010; 376:1579-91.
4. WHO. Updated WHO policy recommendation (October 2012): single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: WHO; Global Malaria Program, 2012.
5. Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization, 2014.
6. Eziefula AC, Gosling R, Hwang J, et al.; Primaquine in Africa Discussion Group. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J 2012; 11:360.
7. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013; 13:175-81.
8. Vulliamy TJ, Othman A, Town M, et al. Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-. Proc Natl Acad Sci U S A 1991; 88:8568-71.
9. Enevold A, Vestergaard LS, Lusingu J, et al. Rapid screening for glucose-6-phosphate dehydrogenase deficiency and haemoglobin polymorphisms in Africa by a simple high-throughput SSOP-ELISA method. Malar J 2005; 4:61.
10. Beutler E. G6PD: population genetics and clinical manifestations. Blood Rev 1996; 10:45-52.
11. Dunyo S, Sirugo G, Sesay S, et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One 2011; 6:e17371.
12. De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R. The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the Seerer population of Senegal. Haematologica 2006; 91:262-3.
13. Clark TG, Fry AE, Auburn S et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet 2009; 17:1080-5.
14. Tine RC, Ndiaye M, Hansson HH, et al. The association between malaria parasitaemia, erythrocyte polymorphisms, malnutrition and anaemia in children less than 10 years in Senegal: a case control study. BMC Res Notes 2012; 5:565.
15. Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med 1998; 76:581-8.
16. Shekalaghe SA, ter Braak R, Daou M, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose- 6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother 2010; 54:1762-8.
17. Greenwood B, Tine R. Primaquine to stop transmission of falciparum malaria. Lancet Infect Dis 2016; 16:623-4.
18. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J 2014; 13:418.
19. Goncalves BP, Tiono AB, Ouedraogo A, et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med 2016; 14:40.
20. Dicko A, Brown JM, Diawara H et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis 2016; 16:674-84.
21. Mwaiswelo R, Ngasala BE, Jovel I et al. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J 2016; 15:316.
22. Senegal Ministere De La Sante Et De La Prevention Et De L'action Sociale. Rapport d'activités 2014. Programme national de lutte contre le paludisme: 2014.
23. Sibille M, Patat A, Caplain H, Donazzolo Y. A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French club phase I working group. Br J Clin Pharmacol 2010; 70:736-48.
24. Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552-9.
25. Adu-Gyasi D, Asante KP, Newton S et al. Evaluation of the diagnostic accuracy of CareStart G6PD deficiency Rapid Diagnostic Test (RDT) in a malaria endemic area in Ghana, Africa. PLoS One 2015; 10:e0125796.
26. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW. Noninferiority of glucose- 6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res 2015; 165:677-88.
27. Committee WHOMPA, Secretariat. Malaria policy advisory committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J 2012; 11:424.
28. Baird K. Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. Pathog Glob Health 2015; 109:93-106.
29. Bancone G, Chowwiwat N, Somsakchaicharoen R et al. Single low dose primaquine (0.25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS One 2016; 11:e0151898.
30. Eziefula AC, Bousema T, Yeung S et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014; 14:130-9.
31. White NJ, Ashley EA, Recht J et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J 2014; 13:483.
32. Graves PM, Gelband H, Garner P. Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 2012; 9:CD008152.
33. Chen IT, Gosling RD. Targeting Plasmodium falciparum transmission with primaquine: same efficacy, improved safety with a lower dose? Expert Rev Clin Pharmacol 2014; 7:681-6.
34. Lin JT, Saunders DL, Meshnick SR. The role of submicroscopic parasitemia in malaria transmission: what is the evidence? Trends Parasitol 2014; 30:183-90.
35. Stone W, Goncalves BP, Bousema T, Drakeley C. Assessing the infectious reservoir of falciparum malaria: past and future. Trends Parasitol 2015; 31:287-96.
36. Johnston GL, Gething PW, Hay SI, Smith DL, Fidock DA. Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Comput Biol 2014; 10:e1003434.
37. Newby G, Hwang J, Koita K et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg 2015; 93:125-34.